Skip to main content

The Latest in HEOR

logo This section of First Report Managed Care focuses on reporting the latest in health care economics and outcomes research for a variety of treatments and disease states.


Early Real-World Data Shows Increased Patient Satisfaction, Demonstrates Effectiveness for AD Therapy
“While this dataset is still maturing, in this as-observed interim analysis of a real-world study, dupilumab demonstrated early and sustained improvement in AD flares, symptoms, and disease control in adults with AD, consistent with that observed in the clinical trial program,” researchers said.


Measuring Real-World Effectiveness of Dupilumab Using IGA Scores to Reduce Symptom Severity
A recent study shows successful reduction of signs, symptoms, and severity of atopic dermatitis based on real-world patient data.


High Persistence Examined With Dupilumab Among Adults With Atopic Dermatitis
Recent data showing high persistence rates for dupilumab therapy in patients with atopic dermatitis suggest that the treatment is well-tolerated and effective.


Lower Outpatient Service Utilization in First- and Second-Line CLL Patients Treated with Ibrutinib Compared With Chemoimmunotherapy 
Treatment with ibrutinib was associated with lower outpatient services compared with traditional chemoimmunotherapy, according to researchers of a study comparing overall health care utilization and costs for patients with CLL.


Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
“In this analysis, emicizumab-kxwh therapy was associated with a decrease in the cost of HEM medications and cost and utilization of medical services,” explained researchers.


Cost-Saving Benefits Associated With Talazoparib Breast Cancer Treatment
When patients with gBRCA1/2mut HER2− advanced breast cancer switched from olaparib to talazoparib, a reduction in costs for US commercial health plans was observed.


Examining Economic Impact of Ixekizumab as Psoriatic Arthritis Treatment
Recent data shows that ixekizumab limits out-of-pocket spending for psoriatic arthritis treatment, despite associated higher pharmacy costs.


Reslizumab Associated With Symptomatic Improvements, Reduced Health Resource Utilization in Adults with Severe Eosinophilic Asthma
According to a study focused on real world data, adults with severe eosinophilic asthma experienced symptomatic improvements and decreased health care resource utilization when treated with reslizumab.


Benralizumab Improved Symptoms, Reduced Exacerbation for Patients With Eosinophilic Severe Asthma
In patients with eosinophilic severe asthma, interleukin-5 receptor α antibody benralizumab improved symptoms and pulmonary function, as well as reduced the frequency of exacerbation, according to a recent study.


Ceritinib Proves Cost Effective in Treating First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer 
Results of a recent study indicate that ceritinib is a cost-effective treatment option for patients with anaplastic lymphoma kinase arrangement non-small-cell lung cancer. 


Ibrutinib Treatment Is Associated with Lower Healthcare Resource Utilization and Net Cost Savings Compared to Chemoimmunotherapy in Front-Line CLL OCM Model Episodes
“Ibrutinib may be a cost-effective means of complying with the OCM aim to increase the value of health care delivered to patients,” authors of the study concluded.

 

Back to Top